Skip to main content

Table 1 Patient eligibility criteria

From: Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial

Inclusion criteria

• Ability to provide written informed consent

• Diagnosis with an asymptomatic AAA which is infrarenal in location and measures ≥50 mm on CTA

• Scheduled for an elective open repair of an AAA

• High likelihood of medication compliance within the 2-week period prior to surgery

Exclusion criteria

• Currently taking fenofibrate or related fibrates

• Contraindication to fenofibrate treatment:

  o Liver impairment as demonstrated by abnormal AST or ALT tests (>1.5 × ULN)

  o Renal impairment as demonstrated by an elevated serum creatinine level (>150 μM)

  o Symptomatic gallbladder disease

  o Previous reaction to any lipid-modifying medication

• Previous infrarenal abdominal aortic surgery

• Mycotic AAA

• Requirement for emergency or urgent open AAA repair

• Current participation in another drug trial

  1. CTA computed tomographic angiography, AAA abdominal aortic aneurysm, AST aspartate aminotransferase, ALT alanine transaminase, ULN upper limit of normal
Back to article page

Trials

ISSN: 1745-6215